United Medical Research Institute | Inglewood, CA

Research site

(Unclaimed)

Location

431-433 North Prairie Avenue, Inglewood, California, United States of America

Site insights

Top conditions

Top treatments

Latanoprost

VRDN-003

Netarsudil

AR-12286

AR-13324

KPI-121

PG324

AGN-190584

DFL24498

Bimatoprost

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 37 total trials

A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study

This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co.,...

Enrolling

Ocular Hypertension (OH)

Primary Open Angle Glaucoma (POAG)

Drug: Bimatoprost ophthalmic solution 0.01% YSBP

Drug: bimatoprost ophthalmic solution 0.01% (Lumigan®)

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract

This is a multicenter, randomized, double-masked, placebo-controlled pilot study conducted in the United States (US) in subjects with age-related cat...

Invitation-only

Age Related Cataracts

Drug: Control

Drug: 0.4% ZOC2017217

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Active, not recruiting

Thyroid Eye Disease (TED)

Drug: VRDN-003

Drug: Placebo

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Active, not recruiting

Open-angle Glaucoma

Ocular Hypertension

Other: Sham Administration

Drug: AGN-193408 SR

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) (REVEAL-1)

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid E...

Active, not recruiting

Thyroid Eye Disease

Drug: VRDN-003

Drug: Placebo

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) (REVEAL-2)

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid...

Active, not recruiting

Thyroid Eye Disease

Drug: Placebo

Drug: VRDN-003

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 t...

Enrolling

Dry Eye Disease (DED)

Other: Vehicle

Drug: DFL24498